Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Thioredoxin domain-containing protein 3 (NME8) is a protein mainly expressed in testis and related tissues, vital for sperm tail maturation and proper ciliary function[1][3][4][5][7][8]. It contains an N-terminal thioredoxin domain and three C-terminal nucleoside diphosphate kinase homology domains, but the enzyme lacks canonical NDK activity. NME8 exhibits 3'-5' exonuclease activity preferentially on single-stranded DNA, implicating it in DNA proofreading and repair. Mutations in NME8 are causative for primary ciliary dyskinesia type 6, a disorder affecting cilia motility that presents as respiratory tract infections, infertility, and laterality defects[1][3][4][5]. NME8 is not currently recognized as a therapeutic drug target, nor are there known interacting drugs or specific safety concerns associated with modulation of its function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Thioredoxin domain-containing protein 3 (NME8).